Sosei Group Corp : Sosei Announces Collaboration with CEOLIA Pharma

Sosei Announces Collaboration with CEOLIA Pharma

Tokyo, Japan - 23 January 2012: Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), announced today that its wholly owned subsidiary Activus Pharma ("Activus") has entered into a Technical Alliance Agreement with CEOLIA Pharma Co., Ltd. ("CEOLIA").
Under the terms of the agreement, CEOLIA and Activus will jointly conduct research and development to assess the feasibility of development of a novel oral formulation using Activus Pure Nano-particle Technology ("APNT").

Enquiries:

Sosei Group Corporation
Tokyo Office	London Office
Milica STOJKOVIC, Investor Relations	Kathryn LYDON, PA to CEO & Corporate Communication
[phone]	[phone]
[e-mail]	[e-mail]

Notes for Editors: About Sosei

Sosei is an international biopharmaceutical company anchored in Japan with a global reach. It practises a reduced risk business model by acquiring compounds from, and bringing compounds into, Japan through exploitation of its unique position within global markets. For further information about Sosei, please visit www.sosei.com.

About CEOLIA

As a speciality pharmaceutical company that focuses on development and commercialization of pharmaceutical products for the sensory organs "ear, nose and throat", CEOLIA is developing its business to become a leading company in such specialized therapeutic area. Through the further enhancement of its product line-up centred around spray technology, CEOLIA will keep supporting the improvement of people's quality of life.

Forward-Looking Statements

This press release contains "forward-looking statements", including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially

1

from those expressed or implied by the forward-looking statements, including adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

2